**Name of Journal:** *World Journal of Stem Cells*

**Manuscript NO:** 67127

**Manuscript Type:** REVIEW

**Molecular mechanism of therapeutic approaches for human gastric cancer stem cells**

Hsieh HL *et al*. Molecular mechanism of cell markers in GCSCs

Hsi-Lung Hsieh, Ming-Chin Yu, Li-Ching Cheng, Ta-Sen Yeh, Ming-Ming Tsai

**Hsi-Lung Hsieh, Li-Ching Cheng, Ming-Ming Tsai,** Department of Nursing, Division of Basic Medical Sciences, Chang-Gung University of Science and Technology, Taoyuan 333, Taiwan

**Hsi-Lung Hsieh, Ming-Ming Tsai,** Research Center for Chinese Herbal Medicine, College of Human Ecology, Chang Gung University of Science and Technology, Taoyuan 333, Taiwan

**Hsi-Lung Hsieh,** Department of Neurology, Chang Gung Memorial Hospital, Taoyuan 333, Taiwan

**Ming-Chin Yu, Ta-Sen Yeh,** Department of General Surgery, Chang Gung Memorial Hospital at Linkou, Taoyuan 333, Taiwan

**Ming-Chin Yu, Ta-Sen Yeh,** College of Medicine, Chang Gung University, Taoyuan 333, Taiwan

**Ming-Chin Yu,** Department of General Surgery, New Taipei Municipal TuCheng Hospital, New Taipei 236, Taiwan

**Ming-Ming Tsai,** Department of General Surgery, Chang Gung Memorial Hospital, Chiayi 613, Taiwan

**Author contributions:** All authors contributed to this paper with conception and design of the study, literature review and analysis, drafting and critical revision and editing, and final approval of the final version; Hsieh HL, Yu MC and Cheng LC have contributed equally to this work.

**Supported by** the Ministry of Science and Technology, Taiwan, No. MOST 108-2320-B-255-002-MY3; Chang Gung Medical Research Foundation, Taoyuan, Taiwan No. CMRPF1I0031, No. CMRPF1I0041, No. CMRPF1I0041-2, and No. CMRPF1L0021; and Chang Gung University of Science and Technology, Taoyuan, Taiwan, No. ZRRPF3J0081, No. ZRRPF3K0111, and No. ZRRPF3L0091.

**Corresponding author: Ming-Ming Tsai, PhD, Associate Professor,** Department of Nursing, Division of Basic Medical Sciences, Chang-Gung University of Science and Technology, No. 261 Wen-hwa 1 Road, Taoyuan 333, Taiwan. mmtsai@mail.cgust.edu.tw

**Received:** April 18, 2021

**Revised:** May 15, 2021

**Accepted: December 21, 2021**

**Published online:**

**Abstract**

Gastric cancer (GC) is a primary cause of cancer-related mortality worldwide, and even after therapeutic gastrectomy, survival rates remain poor. The presence of gastric cancer stem cells (GCSCs) is thought to be the major reason for resistance to anticancer treatment (chemotherapy or radiotherapy), and for the development of tumor recurrence, epithelial–mesenchymal transition, and metastases. Additionally, GCSCs have the capacity for self-renewal, differentiation, and tumor initiation. They also synthesize antiapoptotic factors, demonstrate higher performance of drug efflux pumps, and display cell plasticity abilities. Moreover, the tumor microenvironment (TME; tumor niche) that surrounds GCSCs contains secreted growth factors and supports angiogenesis and is thus responsible for the maintenance of the growing tumor. However, the genesis of GCSCs is unclear and exploration of the source of GCSCs is essential. In this review, we provide up-to-date information about GCSC-surface/intracellular markers and GCSC-mediated pathways and their role in tumor development. This information will support improved diagnosis, novel therapeutic approaches, and better prognosis using GCSC-targeting agents as a potentially effective treatment choice following surgical resection or in combination with chemotherapy and radiotherapy. To date, most anti-GCSC blockers when used alone have been reported as unsatisfactory anticancer agents. However, when used in combination with adjuvant therapy, treatment can improve. By providing insights into the molecular mechanisms of GCSCs associated with tumors in GC, the aim is to optimize anti-GCSCs molecular approaches for GC therapy in combination with chemotherapy, radiotherapy, or other adjuvant treatment.

**Key Words:** Gastric cancer stem cells; Stem cell-surface markers; Tumor niche; Tumor microenvironment

Hsieh HL, Cheng LC, Yu MC, Yeh TS, Tsai MM. Molecular mechanism of therapeutic approaches for human gastric cancer stem cells. *World J Stem Cells* 2021; 0(0): 0000-0000 URL: https://www.wjgnet.com/1948-0210/full/v0/i0/0000.htm

DOI: https://dx.doi.org/10.4252/wjsc.v0.i0.0000

**Core Tip:** In recent years, cancer stem cells (CSCs) have become an extremely important subject in cancer biology. CSCs are considered to be a very small component of tumor tissues, which nevertheless have the capacity for self-renewal, differentiation, and epithelial–mesenchymal transition. CSCs can also explain the clinical phenomenon of resistance to chemotherapy or radiotherapy. Many studies have also found that CSCs are important for cancer initiation and metastasis and play a key role in cancer recurrence. Here, we review GCSC (gastric cancer stem cell)-targeting therapies in GC, including information on GCSC-surface/intracellular markers and GCSC-mediated pathways. This review also provides a brief description of the GCSC niche. Understanding the molecular mechanism of GCSC-targeting agents can help optimize the accuracy of diagnosis and prognosis and the selection of the most appropriate therapy for GC patients.

**INTRODUCTION**

Despite progress in the diagnosis, prognosis, and therapeutic approaches to gastric cancer (GC), it persists as one of the most commonly identified malignant tumors in the world, and with a challenging mortality rate[[1-3](#_ENREF_1)].

The discovery of cancer stem cells (CSCs) has explained much cancer behavior. Although CSCs account for only a small percentage of the entire tumor tissues, these cells are the key components that form the entire tumor. CSCs are viewed as a tumor-initiating subpopulation of cells within tumors capable of self-renewal, which can divide and differentiate into various tumor cell types (intratumoral heterogeneity). They are highly tumorigenic, involved in metastasis, relatively resistant to chemotherapy and radiotherapy, secrete antiapoptotic factors, undergo epithelial-mesenchymal transition (EMT), and display a higher performance of drug efflux pumps[[4-7](#_ENREF_4)]. Opinions regarding the existence, role, and behavior of CSCs differ, suggesting that basic research on CSCs is crucial. Understanding CSCs also gives new ideas for the treatment of cancer. On the premise that targeted killing of CSCs is the fundamental way to completely eliminate tumor tissues, methods specifically focused on CSCs have become a very important topic, the ultimate goal being to design drugs for treatment of GC[[8-11](#_ENREF_8)].

In recent years, due to the rapid development of CSC research, methods used to identify CSCs include evaluation of tumor formation in immune-deficient mice, tumorigenicity, GCSC generation *in vivo*, spheroid colony formation, metastasis, EMT, chemotherapy resistance, radiotherapy resistance, and expression of specific cell-surface/intracellular markers *in vitro*. The GCSC topics to be discussed in this review focus on GCSC-surface/intracellular markers, intracellular markers, the regulation of GCSCs in the tumor microenvironment (TME), and the potential for GCSC-targeted treatments in the future (Figure 1).

**MAIN CELL-SURFACE/INTRACELLULAR MARKERS OF GCSCs**

Since pathologists found that CSCs and SCs have many similarities in histological morphology, the concept that “malignant tumors arise from SCs” is an existing hypothesis[[12](#_ENREF_12),[13](#_ENREF_13)]. Support for this hypothesis was first published in 1994 by Dick *et al* [[14](#_ENREF_14)], who discovered CSCs in acute myeloid leukemia (AML).

In 2003, Singh *et al*[15] showed that CSCs can also be successfully isolated from several solid tumors. CSCs are a common phenomenon in cancer, not all of a specific cancer[[5](#_ENREF_5),[15](#_ENREF_15),[16](#_ENREF_16)]. In solid tumors, the earliest successful isolation of CSCs was in breast cancer, when researchers used cell-surface markers and successfully isolated CSCs[[16](#_ENREF_16)]. Moreover, high tumor-forming ability is an extremely important biological characteristic of CSCs[[15](#_ENREF_15)]. To date, various CSCs have been shown to display different stem cell-surface markers. However, CD44 and CD133 are currently the most commonly used cell-surface markers for the identification of CSCs[[5](#_ENREF_5)]. As noted, because the proportion of each type of CSCs present in solid tumors also differs, it is likely that more cell-surface/intracellular markers will be found in the future that can more accurately determine the presence of CSCs[[5](#_ENREF_5)].

GCSC-surface markers have also been found using flow cytometry in GC cell lines and primary GC tissues, confirming the presence of CSCs in GC[[17-20](#_ENREF_17)], as shown in Table 1[21-49], and other potential GCSC-intracellular markers are summarized in Table 2[23,48,50-57].

***CD44+, CD44H, CD44 splice variants (CD44v), CD44+/CD24+, CD44+/CD54+, EpCAM+/CD44+***

CD44 is a transmembrane glycoprotein that functions as a receptor for hyaluronic acid that is involved in the Wnt/β-catenin pathway that regulates cell migration and homing[[21](#_ENREF_21)]. Takaishi *et al*[[21](#_ENREF_21)] showed that CD44+ was first identified as a common GCSC-surface marker using GC cell lines, which demonstrated spheroid formation ability in *vitro* and established tumorigenicity in *vivo* when injected into immune-deficient mice. Chen *et al*[[22](#_ENREF_22)] reported that CD44+ cells have a sphere-forming ability that can be a cell-surface marker of GCSCs. They also provided a reasonable explanation for the chemoresistance that is frequently observed in GC patients. [Takafumi](https://pubmed.ncbi.nlm.nih.gov/?term=Nishii+T&cauthor_id=19493275) *et al*[[23](#_ENREF_23)] showed that CD44+ cells have higher potential for peritoneal metastasis associated with GCSC-surface markers.

CD44 has two isoforms: CD44H, which reveals a higher affinity for hyaluronic acid, and a CD44 splice variant, CD44v, which displays prometastatic ability. Ishimoto *et al*[[25](#_ENREF_25)] reported that CD44v reduced glutathione (GSH) synthesis and provided protection against reactive oxygen species (ROS). Both CD44H and CD44v may act as GCSC-surface markers.

In addition, CD44+/CD24+ have been examined in GC cell lines and primary GC tissues using flow cytometric analysis[[29](#_ENREF_29)]. It was found that the presence of CD44+/CD24+ was associated with a higher tumorigenicity compared with the control cells (CD44–/CD24–) in an immune-deficient mice model. Hence, these cells have self-renewal and differentiation abilities and the combined expression of CD44+/CD24+ acts as a potential GCSC-surface marker[[29](#_ENREF_29)].

Combined CD44+/CD54+ cells were isolated from the peripheral blood of GC patients and tumor growth similar to the original human tumor was generated when the cells were injected into immune-deficient mice. The same cells can be differentiated into gastric epithelial cells and self-renewed in vitro. These results suggest that the combined CD44+/CD54+ phenotype could be used as a potential cell-surface marker for GCSCs[[30](#_ENREF_30)]. Another group reported that GCSCs also isolated from human tumor tissues and peripheral blood carried CD44+/CD54+ GCSC-surface markers[[22](#_ENREF_22)].

Epithelial cell adhesion molecule (EpCAM)+/CD44+ has also been identified as CSC-surface marker in various types of tumors[[58-61](#_ENREF_58)]. EpCAM+/CD44+ cells from human GC tissues grew into tumors in an immune-deficient mice model, they maintained differentiation potency, and reproduced the intratumoral heterogeneity of the original gastric tumors. EpCAM+/CD44+ cells owned anticancer agents than other subtypes of cells[[31](#_ENREF_31)]. Han *et al*[[31](#_ENREF_31)] demonstrated that EpCAM+/CD44+ cells from GC tissues are viable GCSC-surface markers by using an immune-deficient mice model. However, Rocco *et al*[[62](#_ENREF_62)] reported that CD44+/CD133+ cells displayed neither SC effects nor revealed tumor-initiating effects.

***CD71-***

CD71 belongs to the transferrin receptor that mediates the uptake of transferrin/iron complexes on the surface of red cells. Ohkuma *et al*[[32](#_ENREF_32)] reported that the CD71-cell surface marker was increased in the G1/G0 phase causing cell-cycle arrest, and CD71- cell the invasive heads of cancer motivations, showing CD71- cells have high tumorigenicity, multipotency, and invasiveness abilities. Thus, they suggested that CD71- is a suitable GCSC-surface marker for discovering GC in patients.

***CD90***

CD90 belongs to the immunoglobulin superfamily and the Thy-1 cell-surface antigen (adhesion molecule) family, which is involved in several signal pathways (such as the Notch pathway). Jiang *et al*[[33](#_ENREF_33)] tested CD90+, a well-known CSC-surface marker in gastric primary tumors. They found that CD90+ GC cells can format spheroid populations, undergo self-renewal, and form a tumor hierarchy from human gastric primary tumors *in vitro* and tumorigenicity of gastric primary tumor models *in vivo*. Thus, they suggested that CD90+ is a potential GCSC-surface marker.

***CD133***

CD133 belongs to the pentaspan transmembrane glycoprotein, which is considered to be a hematopoietic SC-surface marker. Zhao *et al*[[63](#_ENREF_63)] verified that CD133 is significantly related to CSC-surface markers in various tumors; however, whether CD133 is also a significant GCSC-surface marker remains unclear[[62](#_ENREF_62),[63](#_ENREF_63)].

***leucine-rich repeat-containing G protein-coupled receptor 5***

leucine-rich repeat-containing G protein-coupled receptor 5 (Lgr5)was identified as a novel normal SC-surface marker of the gastrointestinal tract[[34](#_ENREF_34),[35](#_ENREF_35),[64](#_ENREF_64)]. CD44+, ALDH1+, and CD133+ cell-surface marker cells co-combined with Lgr5+ cells in the SCs of adjacent normal gastric mucosa in GC[[34](#_ENREF_34)]. One group has shown that Lgr5+ cells continuously produced SCs in the gastric glands of transgenic mice under normal homeostatic conditions[[35](#_ENREF_35)]. Another group suggested increased LGR5+ cell-surface marker GCSCs during gastric tumorigenesis may play a role in the development and progression of GC[[36](#_ENREF_36)].

***aldehyde dehydrogenase 1***

aldehyde dehydrogenase 1 (ALDH1) belongs to the aldehyde dehydrogenase family of enzymes that catalyzes the oxidation of aromatic aldehydes to carboxyl acids. Katsuno *et al*[[39](#_ENREF_39)] found ALDH1 to be another novel GCSC-surface/intrcellular marker. The ALDH1+ cells showed higher tumorigenic potential, self-renewal, and produced heterogeneous cell populations compared with ALDH1– cells for a human GC cell line *in vitro* and *in vivo*. In addition, they used transforming growth factor-β (TGF-β) therapy to destroy ALDH1+ cells and their tumorigenicity through downregulation of ALDH1 and regenerating islet-derived protein 4 (REG4)[[39](#_ENREF_39)].

***C-X-C chemokine receptor type 4***

By using microarray analysis, studies have found that C-X-C chemokine receptor type 4+ (CXCR4+) cells can be a novel GCSC-surface marker. CXCR4+ cells can form spheroid colonies, and they have high metastatic ability and chemotherapy resistance *in vitro*. Moreover, CXCR4+ cells have tumorigenicity and GCSC generation capacity in immune-deficient mice *in vivo*. CXCR4+ cells were also found in clinical tissues[[42](#_ENREF_42)].

***Side population, Nanog homeobox, octamer-binding transcription factor 3/4,*** *a****2,*** *a****5,*** *b****3, and*** *b****5 integrins***

Side population (SP) is well known as a CSC-rich population in many tumors[[23](#_ENREF_23),[44](#_ENREF_44),[46](#_ENREF_46),[47](#_ENREF_47)]. GC cell lines have also isolated SP cells[[23](#_ENREF_23),[46](#_ENREF_46),[65](#_ENREF_65)]. Furthermore, studies have confirmed that SP cells showed higher engrafted tumor formation and peritoneal metastasis with overexpression levels of adhesion molecules (such as α2, α5, β3, and β5 integrins) and CD44 compared with those of the non-SP cells in GC cell lines. Moreover, the mRNA overexpression of GCSC markers ALDH1, CD44, Nanog homeobox (NANOG), and octamer-binding transcription factor 3/4 (OCT3/4) was significant in SP cells, which are similar to CSCs[[23](#_ENREF_23)]. Fukuda *et al*[[46](#_ENREF_46)] described similar results and found that SP cells are more tumorigenic and chemoresistant compared with non-SP cells in GC cell lines and human GC tissues, which remain in an undifferentiated state and display a different hierarchy in malignancy.

Ehata *et al*[[66](#_ENREF_66)] found that SP cells display greater tumorigenicity, self-renewal activity, and multipotency of SC phenotypes *in vivo* compared with non-SP cells in human diffuse-type GC cells but not intestinal-type GC cells. Another group reported that SP cells were smaller and expressed CD133 and MSI-1, which yielded SP and non-SP cells in recultivation experiments[[44](#_ENREF_44)]. Elsewhere it was reported that SP cells also have GCSC properties in the MKN-45 GC cell line. However, SP cells did not have GCSC properties in BGC823 and other GC cell lines[[21](#_ENREF_21),[48](#_ENREF_48),[67](#_ENREF_67)]. Nevertheless, using the SP cell assay to isolate GCSCs remains debatable.

***ATP-binding cassette subfamily B member 1/multidrug resistance protein 1 and ATP-binding cassette subfamily G member 2***

Jiang *et al*[[33](#_ENREF_33)] demonstrated the overexpression of the GCSC markers ATP-binding cassette subfamily B member 1/multidrug resistance protein 1 (ABCB1/MDR1) and ATP-binding cassette subfamily G member 2 (ABCG2) of SP cells in human GC tissues and several GC cell lines. Previous studies found that ABCB1/MDR1 and ABCG2 belong to ABC transporters, which can remove toxic multidrugs extracellularly causing chemoresistance of GCSCs. The expression of these transporters is related to the response to therapy and survival for GC patients[[23](#_ENREF_23),[43-45](#_ENREF_43)].

***Dedicator of cytokinesis 6***

Chi *et al*[[50](#_ENREF_50)] revealed that overexpression of dedicator of cytokinesis 6 (DOCK6) promoted chemoresistance, radioresistance, GC progression, and independent biomarkers of GC prognosis through the Rac family small GTPase 1 (Rac1) activation in the WNT/β-catenin signaling pathway. DOCK6 acts as a guanine nucleotide exchange factor (GEF) for Rac1 and CDC42. These results suggest that DOCK6 is a novel GCSC marker in GC cell lines, animal models, and clinical GC tissues[[50](#_ENREF_50)].

***Muscle, intestine, and stomach expression 1***

Previous studies found that muscle, intestine, and stomach expression 1 (Mist1)+ SCs act as an initial cell for intestinal-type GC combined with K-RAS and APC mutations. On the other hand, Mist1+ SCs act as an initial cell for diffuse-type GC development that is dependent on an inflammation-mediated GCSC niche including [endothelial cells](https://www.sciencedirect.com/topics/medicine-and-dentistry/endothelial-cell) secreting C-X-C motif chemokine ligand 12+ ***(***CXCL12+) and CXCR4+ gastric innate [lymphoid cells](https://www.sciencedirect.com/topics/medicine-and-dentistry/lymphoid-cell) (ILCs) secreting Wnt5a to activate RhoA in the loss of E-cadherin GC cells[[51](#_ENREF_51)].

***Leucine-rich repeats and immunoglobulin-like domains protein 1***

Leucine-rich repeats and immunoglobulin-like domains protein 1 (Lrig1)+ (a pan-ErbB inhibitor) GCSCs are involved in cell-cycle repression and response to oxidative damage. Loss of APC in Lrig1+ cells leads to intestinal-type GC, or [genetic](https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/genetic-ablation) loss of Lrig1 resulting in higher expression of ErbB1-3[56].

***Sex-determining region Y-box 2***

Microarray studies have found that aberrant expression of sex-determining region Y-box 2 (SOX2) has been observed in GCs. SOX2 transcriptional activity can promote cell proliferation and migration, antiapoptosis, and chemoresistance, and suppress changes in cell cycle and tumorigenic potential in vitro and in vivo for GC development and progression[[54](#_ENREF_54)]. These putative markers may be suitable to isolate GCSCs and offer new insights into novel approaches for GC therapy by targeting GCSCs in clinical trials. It is important to note that most published markers are not specific to GC. Moreover, different GCSCs may coexist within the same tumor mass. Thus, these putative marker GCSCs may also contain SCs and progenitor cells. Therefore, in terms of targeted therapy, identification of a single cell-intracellular marker on GCSCs may not be enough to kill all GCSCs, and thus, a combination of these GCSC markers is essential.

**GCSCs REGULATE SIGNALING PATHWAYS IN THE TUMOR NICHE**

In recent years, it has been discovered that it is impossible to treat a differentiated tumor without knowing exactly the true group of CSCs. However, normal cancer cells (non-CSCs) can be affected by the TME, epigenetic regulation, and other factors leading to dedifferentiation and a manifestation of CSCs. Therefore, CSCs are a dynamic balance. CSCs can be regulated by stromal cells or could differentiate into tumors with several populations. While internally differentiated tumor populations can occur, dedifferentiation under the influence of the microenvironment can cause cells to revert to CSCs. This idea has greatly affected our biological knowledge of malignant tumors. Awareness of cancer treatment, especially evaluation of treatment that is effective for CSCs, with novel methods of clinical trials should be rethought[[10](#_ENREF_10),[68](#_ENREF_68)].

In addition, CSCs express specific cell-surface/intracellular antigens, and the signaling pathways also differ from non-CSCs, reflecting the characteristics of the cells. Figure 2 shows that non-CSCs can be regulated in the external environment, in signal transmission, and in epigenetic modification[[69](#_ENREF_69)]. The ability to dedifferentiate under genetic control displays a specific characteristic of CSCs[[6](#_ENREF_6),[70-72](#_ENREF_70)].

There are several signaling pathways involved in the drive and maintenance of CSCs in both normal and cancer cells (non-CSCs) (Figure 3).

***Hedgehog pathway***

The Hedgehog pathway has a primary role in cell differentiation and normal vertebrate embryonic development[[27](#_ENREF_27)]. The Hedgehog pathway, which regulates adult SCs in tissue maintenance and repair, is inactive in most adult tissues. However, activation of the Hedgehog pathway induces tumor progression and radiation resistance in several cancers to cause mutations in the patched homolog 1 (PTCH1) and smoothened (SMO; frizzled family receptor) genes in patients[[31](#_ENREF_31)].

***Notch/STAT3 pathway***

In several cancers, the activation of the STAT family (such as STAT1, STAT3, STAT4, STAT5a, STAT5b, and STAT6) *via* phosphorylation of a specific tyrosine kinase residue promotes tumor growth and metastasis. Among them, STAT3 activation plays a key role in tumor progression[[73](#_ENREF_73)]. Studies show that the action of many protein tyrosine kinases, oncogenes, IL-17, and viruses is mediated *via* activation of the downstream phosphorylated STAT3 transcription factor pathway. These actions include cellular proliferation, invasion, migration, antiapoptosis, and angiogenesis in GCSCs[[74](#_ENREF_74)]. Additionally, STAT3 upregulated cyclin D1 and c-Myc expression, contributing to enhanced cell-cycle progression in cancer cells. Interestingly, targeting STAT3 activation suppresses tumor growth and metastasis, without affecting normal cells *in vitro* and *in vivo*, suggesting that STAT3 could be effective for GCSC-targeting therapy[[75](#_ENREF_75)].

***NANOG pathway***

In embryonic SCs, signal transducer and activator of transcription 3 (STAT3) forms a complex with NANOG for maintaining SC pluripotency. Various studies propose that NANOG may act as an oncogene to be activated in several cancers in which overexpression correlates with poor survival promoting oncogenesis in patients[[76](#_ENREF_76)].

***Wnt/β-catenin pathway***

Wnt ligands are produced from cells in the SC microenvironment, and the Wnt/β-catenin pathway has been identified for its role in CSC self-renewal and radiation-resistant pathways[[30](#_ENREF_30),[77](#_ENREF_77)]. Wnt signaling is associated with EMT with a poor clinical outcome[[78](#_ENREF_78)].

Due to CSCs have chemotherapy resistant treatments associated with GCSC-related signaling pathways and develops CSCs targeted therapy[[79](#_ENREF_79),[80](#_ENREF_80)]. The research on CSC signaling pathways is still preliminary. Their functional regulatory mechanisms are worthy of advanced discussion regarding the similarities and differences of signaling pathways between differentiated cancer cells (non-CSCs) and CSCs. A solution to these problems can help understand the resistance phenomenon caused by clinical treatment of tumors, and design approaches that could provide an important reference for anti-CSCs targeting drugs[[81](#_ENREF_81)]. Therefore, these CSC-related pathways are commonly new targets for the development of anticancer drugs or inhibitors in various clinical trials[[69](#_ENREF_69),[82](#_ENREF_82)] (Table 3)[27,28,73,75-78,83-86].

**CURRENT TREATMENT OF THE POTENTIAL FOR TARGETING GCSCs**

In general, most of the initial tumor appears reduced in size after treatment. However, the appearance of drug resistance after treatment is common because a subpopulation of differentiated cancer cells (non-CSCs) develops drug resistance. CSCs are more resistant to conventional chemotherapy, EMT, more antiapoptotic factors, and higher performance of drug efflux pumps than differentiated cancer cells (non-CSCs)[[6](#_ENREF_6),[8](#_ENREF_8),[71](#_ENREF_71),[72](#_ENREF_72)].

The reason CSC theory has received considerable attention in recent years is because CSCs can escape the poison of chemotherapy drugs, which can explain the failure of chemotherapy.

Usually CSCs are parked in the cell cycle G0 phase, that is, they will not enter the cell cycle. Currently, most chemotherapeutic drugs focus on inhibiting the cell cycle in a growing cell. The growth of differentiated cancer cells (non-CSCs) in the cell cycle can be prevented, but the drugs cannot kill CSCs. Once chemotherapy is over, the surviving CSCs will regenerate and proliferate, leading to the recurrence of cancer. Because some studies show that chemotherapeutic drugs may promote CSCs after treatment, it is recommended to use two-stage therapy to kill CSCs. Therefore, the first stage is to promote CSCs into the cell cycle, and the second stage uses chemotherapy drugs or targeted CSC therapy to kill CSCs[[87](#_ENREF_87)]. Several studies have indicated that CSCs promote recurrence after chemotherapy[[6](#_ENREF_6)].

It has also been reported that CSCs will increase tumor cell invasion, EMT, and metastatic ability[[4-7](#_ENREF_4)]. Another group pointed out that CSCs will increase the protein level of the chemokine receptor CXCR4; thus, CSCs will follow the of its stromal cell-derived factor-1 (SDF-1; CXCR4 ligand) concentration degree of metastasis, from the original position (low levels of SDF-1) in CSCs microenvironment (tumor niche) transfer to any tissue that exhibits high levels of SDF-1. CXCR4 neutralizing antibody can effectively inhibit CSC metastasis in nude mice. These results confirm that CSC cells can indeed promote cancer EMT, metastasis, and invasion abilities[47].

Wang *et al*[[88](#_ENREF_88)] and Ricci-Vitiani *et al*[[89](#_ENREF_89)] found that glioma cells are derived from neuron-like glioma stem cells. They also found that the tumor tissue and the tumor inside vascular ECs (vascular endothelial cells) both have the same aberrant genes. Researchers have found that these tumor-derived vascular ECs come from CSCs, that is, CSCs can differentiate into vascular ECs to form new blood vessels. This result challenges the existing belief that the internal vascular ECs of a tumor are normal cells. It also explains why combretastatin A-4 (a vascular disrupting agent) can selectively abolish the existing tumor vascular ECs but is less harmful to normal blood vessels.

**FURTHER CHALLENGES OF ANTIGCSCs THERAPY**

Currently, scholars have different opinions on the origin of GCSCs. Additionally, various tumors do not have the same origin of CSCs and our understanding needs to be deepened. Importantly, GCSCs play an important role in the occurrence and development of tumors, EMT, metastasis, recurrence, and prognosis.

If only GCSCs are removed, is such treatment sufficient? Obviously, differentiated cancer cells (non-CSCs) also need targeted therapy. Moreover, both GCSCs and their differentiated cancer cells (non-CSCs) require effective targeted therapy. In the future, newly developed drugs will provide opportunities for successful cancer treatment to improve the patient’s prognosis. Efficacy of these drugs must first be confirmed by clinical trials.

Given that research in GCSCs is an emerging field, many details remain unclear, and future GCSC research will need to focus on several key issues: (1) the determination of GCSC-specific molecules of cell-surface/intracellular markers; (2) the environment of the GCSC niche, the interaction and molecular mechanism between the GCSC tumor niche and GCs; (3) the molecular mechanism of malignant transformation/EMT of normal SCs; (4) the need to verify and clarify the mechanism of GCSC chemo-/radioresistance therapy; (5) exploration and development of therapeutic approaches for GCSCs; and (6) overall, monitoring of the role of GCSCs to evaluate the indicators (monitoring circulating tumor cells), it means that may appear for new metastatic lesions which can be early detected. Therefore, with the evaluation of clinical trials involving GCSCs, the results of GCSC therapy will help improve anticancer treatment. GCSC-targeted drug therapy alone may not be sufficient to fight cancer, but combined treatment can improve treatment results. Finally, GCSC theory provides a new way to evaluate anticancer drugs in clinical trials and provide a framework for effective drug development. We believe that cancer can be cured, or at least, become a chronic and controllable disease; this goal will surely be achieved in the future.

Following improvements in research technology, it is hoped that a better understanding of GCSC-surface/intracellular markers and related signal pathways will help antitumor growth, early diagnosis, GCSC-targeted drug therapy, antimetastasis, anti-EMT, as well as recurrence prevention and prognosis judgment, all of which have significant therapeutic application.

**CONCLUSION**

In recent years, an increasing number of studies have highlighted that CSCs are indeed tumor-initiating cells in cancer tissues. These cells may not be a single homogeneous cell: different tissues or different patients have different tumor initiation cells. The more we understand these GCSCs or tumor-initiating cells, the better we can design drugs to kill them, such as using second-stage therapy to kill GCSCs[[87](#_ENREF_87)] or designing a monoclonal Ab (antibody) or small interference RNA (siRNA) that blocks GCSC-surface/intracellular markers. For example, CD44 can promote the differentiation of GCSCs to complete the treatment. With the joint efforts of basic researchers and clinicians, the hope is that cancer can be effectively controlled in the future.

**ACKNOWLEDGEMENTS**

The corresponding author would like to thank the *World Journal of Stem Cells*for the opportunity and acknowledge the hard work of all supporting authors.

**REFERENCES**

1 **Baniak N**, Senger JL, Ahmed S, Kanthan SC, Kanthan R. Gastric biomarkers: a global review. *World J Surg Oncol* 2016; **14**: 212 [PMID: 27514667 DOI: 10.1186/s12957-016-0969-3]

2 **Kwon KJ**, Shim KN, Song EM, Choi JY, Kim SE, Jung HK, Jung SA. Clinicopathological characteristics and prognosis of signet ring cell carcinoma of the stomach. *Gastric Cancer* 2014; **17**: 43-53 [PMID: 23389081 DOI: 10.1007/s10120-013-0234-1]

3 **Bertuccio P**, Chatenoud L, Levi F, Praud D, Ferlay J, Negri E, Malvezzi M, La Vecchia C. Recent patterns in gastric cancer: a global overview. *Int J Cancer* 2009; **125**: 666-673 [PMID: 19382179 DOI: 10.1002/ijc.24290]

4 **Dalerba P**, Cho RW, Clarke MF. Cancer stem cells: models and concepts. *Annu Rev Med* 2007; **58**: 267-284 [PMID: 17002552 DOI: 10.1146/annurev.med.58.062105.204854]

5 **Visvader JE**, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. *Nat Rev Cancer* 2008; **8**: 755-768 [PMID: 18784658 DOI: 10.1038/nrc2499]

6 **Poleszczuk J**, Hahnfeldt P, Enderling H. Evolution and phenotypic selection of cancer stem cells. *PLoS Comput Biol* 2015; **11**: e1004025 [PMID: 25742563 DOI: 10.1371/journal.pcbi.1004025]

7 **Hohenberger P**, Gretschel S. Gastric cancer. *Lancet* 2003; **362**: 305-315 [PMID: 12892963 DOI: 10.1016/s0140-6736(03)13975-x]

8 **Vermeulen L**, de Sousa e Melo F, Richel DJ, Medema JP. The developing cancer stem-cell model: clinical challenges and opportunities. *Lancet Oncol* 2012; **13**: e83-e89 [PMID: 22300863 DOI: 10.1016/S1470-2045(11)70257-1]

9 **Clarke MF**, Fuller M. Stem cells and cancer: two faces of eve. *Cell* 2006; **124**: 1111-1115 [PMID: 16564000 DOI: 10.1016/j.cell.2006.03.011]

10 **Visvader JE**, Lindeman GJ. Cancer stem cells: current status and evolving complexities. *Cell Stem Cell* 2012; **10**: 717-728 [PMID: 22704512 DOI: 10.1016/j.stem.2012.05.007]

11 **Jordan CT**, Guzman ML, Noble M. Cancer stem cells. *N Engl J Med* 2006; **355**: 1253-1261 [PMID: 16990388 DOI: 10.1056/NEJMra061808]

12 **Huntly BJ**, Gilliland DG. Leukaemia stem cells and the evolution of cancer-stem-cell research. *Nat Rev Cancer* 2005; **5**: 311-321 [PMID: 15803157 DOI: 10.1038/nrc1592]

13 **Furth J**. Transmission of myeloid leukemia of mice: its relation to myeloma. *J Exp Med* 1935; **61**: 423-446 [PMID: 19870369 DOI: 10.1084/jem.61.3.423]

14 **Lapidot T**, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, Minden M, Paterson B, Caligiuri MA, Dick JE. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. *Nature* 1994; **367**: 645-648 [PMID: 7509044 DOI: 10.1038/367645a0]

15 **Singh SK**, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, Dirks PB. Identification of a cancer stem cell in human brain tumors. *Cancer Res* 2003; **63**: 5821-5828 [PMID: 14522905]

16 **Al-Hajj M**, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. *Proc Natl Acad Sci USA* 2003; **100**: 3983-3988 [PMID: 12629218 DOI: 10.1073/pnas.0530291100]

17 **Greve B**, Kelsch R, Spaniol K, Eich HT, Götte M. Flow cytometry in cancer stem cell analysis and separation. *Cytometry A* 2012; **81**: 284-293 [PMID: 22311742 DOI: 10.1002/cyto.a.22022]

18 **Xu G**, Shen J, Ou Yang X, Sasahara M, Su X. Cancer stem cells: the 'heartbeat' of gastric cancer. *J Gastroenterol* 2013; **48**: 781-797 [PMID: 23184096 DOI: 10.1007/s00535-012-0712-y]

19 **Singh SR**. Gastric cancer stem cells: a novel therapeutic target. *Cancer Lett* 2013; **338**: 110-119 [PMID: 23583679 DOI: 10.1016/j.canlet.2013.03.035]

20 **Vermeulen L**, Todaro M, de Sousa Mello F, Sprick MR, Kemper K, Perez Alea M, Richel DJ, Stassi G, Medema JP. Single-cell cloning of colon cancer stem cells reveals a multi-lineage differentiation capacity. *Proc Natl Acad Sci USA* 2008; **105**: 13427-13432 [PMID: 18765800 DOI: 10.1073/pnas.0805706105]

21 **Takaishi S**, Okumura T, Tu S, Wang SS, Shibata W, Vigneshwaran R, Gordon SA, Shimada Y, Wang TC. Identification of gastric cancer stem cells using the cell surface marker CD44. *Stem Cells* 2009; **27**: 1006-1020 [PMID: 19415765 DOI: 10.1002/stem.30]

22 **Chen W**, Zhang X, Chu C, Cheung WL, Ng L, Lam S, Chow A, Lau T, Chen M, Li Y, Nie Y, Wong BC, Pang R. Identification of CD44+ cancer stem cells in human gastric cancer. *Hepatogastroenterology* 2013; **60**: 949-954 [PMID: 23478146 DOI: 10.5754/hge12881]

23 **Nishii T**, Yashiro M, Shinto O, Sawada T, Ohira M, Hirakawa K. Cancer stem cell-like SP cells have a high adhesion ability to the peritoneum in gastric carcinoma. *Cancer Sci* 2009; **100**: 1397-1402 [PMID: 19493275 DOI: 10.1111/j.1349-7006.2009.01211.x]

24 **Flores-Téllez TN**, Villa-Treviño S, Piña-Vázquez C. Road to stemness in hepatocellular carcinoma. *World J Gastroenterol* 2017; **23**: 6750-6776 [PMID: 29085221 DOI: 10.3748/wjg.v23.i37.6750]

25 **Ishimoto T**, Nagano O, Yae T, Tamada M, Motohara T, Oshima H, Oshima M, Ikeda T, Asaba R, Yagi H, Masuko T, Shimizu T, Ishikawa T, Kai K, Takahashi E, Imamura Y, Baba Y, Ohmura M, Suematsu M, Baba H, Saya H. CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth. *Cancer Cell* 2011; **19**: 387-400 [PMID: 21397861 DOI: 10.1016/j.ccr.2011.01.038]

26 **Knochelmann HM**, Dwyer CJ, Bailey SR, Amaya SM, Elston DM, Mazza-McCrann JM, Paulos CM. When worlds collide: Th17 and Treg cells in cancer and autoimmunity. *Cell Mol Immunol* 2018; **15**: 458-469 [PMID: 29563615 DOI: 10.1038/s41423-018-0004-4]

27 **Scales SJ**, de Sauvage FJ. Mechanisms of Hedgehog pathway activation in cancer and implications for therapy. *Trends Pharmacol Sci* 2009; **30**: 303-312 [PMID: 19443052 DOI: 10.1016/j.tips.2009.03.007]

28 **Akyala AI**, Peppelenbosch MP. Gastric cancer and Hedgehog signaling pathway: emerging new paradigms. *Genes Cancer* 2018; **9**: 1-10 [PMID: 29725500 DOI: 10.18632/genesandcancer.168]

29 **Zhang C**, Li C, He F, Cai Y, Yang H. Identification of CD44+CD24+ gastric cancer stem cells. *J Cancer Res Clin Oncol* 2011; **137**: 1679-1686 [PMID: 21882047 DOI: 10.1007/s00432-011-1038-5]

30 **Chen T**, Yang K, Yu J, Meng W, Yuan D, Bi F, Liu F, Liu J, Dai B, Chen X, Wang F, Zeng F, Xu H, Hu J, Mo X. Identification and expansion of cancer stem cells in tumor tissues and peripheral blood derived from gastric adenocarcinoma patients. *Cell Res* 2012; **22**: 248-258 [PMID: 21727908 DOI: 10.1038/cr.2011.109]

31 **Han ME**, Jeon TY, Hwang SH, Lee YS, Kim HJ, Shim HE, Yoon S, Baek SY, Kim BS, Kang CD, Oh SO. Cancer spheres from gastric cancer patients provide an ideal model system for cancer stem cell research. *Cell Mol Life Sci* 2011; **68**: 3589-3605 [PMID: 21448722 DOI: 10.1007/s00018-011-0672-z]

32 **Ohkuma M**, Haraguchi N, Ishii H, Mimori K, Tanaka F, Kim HM, Shimomura M, Hirose H, Yanaga K, Mori M. Absence of CD71 transferrin receptor characterizes human gastric adenosquamous carcinoma stem cells. *Ann Surg Oncol* 2012; **19**: 1357-1364 [PMID: 21523522 DOI: 10.1245/s10434-011-1739-7]

33 **Jiang Y**, He Y, Li H, Li HN, Zhang L, Hu W, Sun YM, Chen FL, Jin XM. Expressions of putative cancer stem cell markers ABCB1, ABCG2, and CD133 are correlated with the degree of differentiation of gastric cancer. *Gastric Cancer* 2012; **15**: 440-450 [PMID: 22395309 DOI: 10.1007/s10120-012-0140-y]

34 **Wu C**, Xie Y, Gao F, Wang Y, Guo Y, Tian H, Li Y, Fan W. Lgr5 expression as stem cell marker in human gastric gland and its relatedness with other putative cancer stem cell markers. *Gene* 2013; **525**: 18-25 [PMID: 23664892 DOI: 10.1016/j.gene.2013.04.067]

35 **Barker N**, Huch M, Kujala P, van de Wetering M, Snippert HJ, van Es JH, Sato T, Stange DE, Begthel H, van den Born M, Danenberg E, van den Brink S, Korving J, Abo A, Peters PJ, Wright N, Poulsom R, Clevers H. Lgr5(+ve) stem cells drive self-renewal in the stomach and build long-lived gastric units in vitro. *Cell Stem Cell* 2010; **6**: 25-36 [PMID: 20085740 DOI: 10.1016/j.stem.2009.11.013]

36 **Simon E**, Petke D, Böger C, Behrens HM, Warneke V, Ebert M, Röcken C. The spatial distribution of LGR5+ cells correlates with gastric cancer progression. *PLoS One* 2012; **7**: e35486 [PMID: 22530031 DOI: 10.1371/journal.pone.0035486]

37 **Li X**, Bu W, Meng L, Liu X, Wang S, Jiang L, Ren M, Fan Y, Sun H. CXCL12/CXCR4 pathway orchestrates CSC-like properties by CAF recruited tumor associated macrophage in OSCC. *Exp Cell Res* 2019; **378**: 131-138 [PMID: 30857971 DOI: 10.1016/j.yexcr.2019.03.013]

38 **Gong X**, Azhdarinia A, Ghosh SC, Xiong W, An Z, Liu Q, Carmon KS. LGR5-Targeted Antibody-Drug Conjugate Eradicates Gastrointestinal Tumors and Prevents Recurrence. *Mol Cancer Ther* 2016; **15**: 1580-1590 [PMID: 27207778 DOI: 10.1158/1535-7163.MCT-16-0114]

39 **Katsuno Y**, Ehata S, Yashiro M, Yanagihara K, Hirakawa K, Miyazono K. Coordinated expression of REG4 and aldehyde dehydrogenase 1 regulating tumourigenic capacity of diffuse-type gastric carcinoma-initiating cells is inhibited by TGF-β. *J Pathol* 2012; **228**: 391-404 [PMID: 22430847 DOI: 10.1002/path.4020]

40 **Nguyen PH**, Giraud J, Chambonnier L, Dubus P, Wittkop L, Belleannée G, Collet D, Soubeyran I, Evrard S, Rousseau B, Senant-Dugot N, Mégraud F, Mazurier F, Varon C. Characterization of Biomarkers of Tumorigenic and Chemoresistant Cancer Stem Cells in Human Gastric Carcinoma. *Clin Cancer Res* 2017; **23**: 1586-1597 [PMID: 27620279 DOI: 10.1158/1078-0432.CCR-15-2157]

41 **Han J**, Won M, Kim JH, Jung E, Min K, Jangili P, Kim JS. Cancer stem cell-targeted bio-imaging and chemotherapeutic perspective. *Chem Soc Rev* 2020; **49**: 7856-7878 [PMID: 32633291 DOI: 10.1039/d0cs00379d]

42 **Fujita T**, Chiwaki F, Takahashi RU, Aoyagi K, Yanagihara K, Nishimura T, Tamaoki M, Komatsu M, Komatsuzaki R, Matsusaki K, Ichikawa H, Sakamoto H, Yamada Y, Fukagawa T, Katai H, Konno H, Ochiya T, Yoshida T, Sasaki H. Identification and Characterization of CXCR4-Positive Gastric Cancer Stem Cells. *PLoS One* 2015; **10**: e0130808 [PMID: 26110809 DOI: 10.1371/journal.pone.0130808]

43 **Gottesman MM**, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. *Nat Rev Cancer* 2002; **2**: 48-58 [PMID: 11902585 DOI: 10.1038/nrc706]

44 **Schmuck R**, Warneke V, Behrens HM, Simon E, Weichert W, Röcken C. Genotypic and phenotypic characterization of side population of gastric cancer cell lines. *Am J Pathol* 2011; **178**: 1792-1804 [PMID: 21435459 DOI: 10.1016/j.ajpath.2010.12.043]

45 **Yashiro M**, Nishii T, Hasegawa T, Matsuzaki T, Morisaki T, Fukuoka T, Hirakawa K. A c-Met inhibitor increases the chemosensitivity of cancer stem cells to the irinotecan in gastric carcinoma. *Br J Cancer* 2013; **109**: 2619-2628 [PMID: 24129235 DOI: 10.1038/bjc.2013.638]

46 **Fukuda K**, Saikawa Y, Ohashi M, Kumagai K, Kitajima M, Okano H, Matsuzaki Y, Kitagawa Y. Tumor initiating potential of side population cells in human gastric cancer. *Int J Oncol* 2009; **34**: 1201-1207 [PMID: 19360333]

47 **Haraguchi N**, Inoue H, Tanaka F, Mimori K, Utsunomiya T, Sasaki A, Mori M. Cancer stem cells in human gastrointestinal cancers. *Hum Cell* 2006; **19**: 24-29 [PMID: 16643604 DOI: 10.1111/j.1749-0774.2005.00004.x]

48 **Burkert J**, Otto WR, Wright NA. Side populations of gastrointestinal cancers are not enriched in stem cells. *J Pathol* 2008; **214**: 564-573 [PMID: 18266310 DOI: 10.1002/path.2307]

49 **Powell AE**, Wang Y, Li Y, Poulin EJ, Means AL, Washington MK, Higginbotham JN, Juchheim A, Prasad N, Levy SE, Guo Y, Shyr Y, Aronow BJ, Haigis KM, Franklin JL, Coffey RJ. The pan-ErbB negative regulator Lrig1 is an intestinal stem cell marker that functions as a tumor suppressor. *Cell* 2012; **149**: 146-158 [PMID: 22464327 DOI: 10.1016/j.cell.2012.02.042]

50 **Chi HC**, Tsai CY, Wang CS, Yang HY, Lo CH, Wang WJ, Lee KF, Lai LY, Hong JH, Chang YF, Tsai MM, Yeh CT, Wu CH, Hsieh CC, Wang LH, Chen WJ, Lin KH. DOCK6 promotes chemo- and radioresistance of gastric cancer by modulating WNT/β-catenin signaling and cancer stem cell traits. *Oncogene* 2020; **39**: 5933-5949 [PMID: 32753649 DOI: 10.1038/s41388-020-01390-0]

51 **Hayakawa Y**, Ariyama H, Stancikova J, Sakitani K, Asfaha S, Renz BW, Dubeykovskaya ZA, Shibata W, Wang H, Westphalen CB, Chen X, Takemoto Y, Kim W, Khurana SS, Tailor Y, Nagar K, Tomita H, Hara A, Sepulveda AR, Setlik W, Gershon MD, Saha S, Ding L, Shen Z, Fox JG, Friedman RA, Konieczny SF, Worthley DL, Korinek V, Wang TC. Mist1 Expressing Gastric Stem Cells Maintain the Normal and Neoplastic Gastric Epithelium and Are Supported by a Perivascular Stem Cell Niche. *Cancer Cell* 2015; **28**: 800-814 [PMID: 26585400 DOI: 10.1016/j.ccell.2015.10.003]

52 **Chambers I**, Tomlinson SR. The transcriptional foundation of pluripotency. *Development* 2009; **136**: 2311-2322 [PMID: 19542351 DOI: 10.1242/dev.024398]

53 **Masui S**, Nakatake Y, Toyooka Y, Shimosato D, Yagi R, Takahashi K, Okochi H, Okuda A, Matoba R, Sharov AA, Ko MS, Niwa H. Pluripotency governed by Sox2 via regulation of Oct3/4 expression in mouse embryonic stem cells. *Nat Cell Biol* 2007; **9**: 625-635 [PMID: 17515932 DOI: 10.1038/ncb1589]

54 **Hütz K**, Mejías-Luque R, Farsakova K, Ogris M, Krebs S, Anton M, Vieth M, Schüller U, Schneider MR, Blum H, Wagner E, Jung A, Gerhard M. The stem cell factor SOX2 regulates the tumorigenic potential in human gastric cancer cells. *Carcinogenesis* 2014; **35**: 942-950 [PMID: 24325912 DOI: 10.1093/carcin/bgt410]

55 **Johansson H**, Simonsson S. Core transcription factors, Oct4, Sox2 and Nanog, individually form complexes with nucleophosmin (Npm1) to control embryonic stem (ES) cell fate determination. *Aging (Albany NY)* 2010; **2**: 815-822 [PMID: 21076177 DOI: 10.18632/aging.100222]

56 **Sultan M**, Coyle KM, Vidovic D, Thomas ML, Gujar S, Marcato P. Hide-and-seek: the interplay between cancer stem cells and the immune system. *Carcinogenesis* 2017; **38**: 107-118 [PMID: 27866156 DOI: 10.1093/carcin/bgw115]

57 **Bouriez D**, Giraud J, Gronnier C, Varon C. Efficiency of All-Trans Retinoic Acid on Gastric Cancer: A Narrative Literature Review. *Int J Mol Sci* 2018; **19** [PMID: 30380687 DOI: 10.3390/ijms19113388]

58 **Marhaba R**, Klingbeil P, Nuebel T, Nazarenko I, Buechler MW, Zoeller M. CD44 and EpCAM: cancer-initiating cell markers. *Curr Mol Med* 2008; **8**: 784-804 [PMID: 19075676 DOI: 10.2174/156652408786733667]

59 **Prall F**, Maletzki C, Linnebacher M. The EpCAM high/CD44 high colorectal carcinoma stem cell phenotype is not preferentially expressed in tumour buds. *Histopathology* 2010; **56**: 553-555 [PMID: 20459564 DOI: 10.1111/j.1365-2559.2010.03502.x]

60 **Masciale V**, Grisendi G, Banchelli F, D'Amico R, Maiorana A, Sighinolfi P, Stefani A, Morandi U, Dominici M, Aramini B. CD44+/EPCAM+ cells detect a subpopulation of ALDHhigh cells in human non-small cell lung cancer: A chance for targeting cancer stem cells? *Oncotarget* 2020; **11**: 1545-1555 [PMID: 32391123 DOI: 10.18632/oncotarget.27568]

61 **Gu Q**, Chen X, Zhou L, Liu X. Exosome EpCAM promotes the metastasis of glioma by targeting the CD44 signaling molecule on the surface of glioma cells. *Adv Clin Exp Med* 2020; **29**: 1277-1282 [PMID: 33269813 DOI: 10.17219/acem/126051]

62 **Rocco A**, Liguori E, Pirozzi G, Tirino V, Compare D, Franco R, Tatangelo F, Palaia R, D'Armiento FP, Pollastrone G, Affuso A, Bottazzi EC, Masone S, Persico G, Nardone G. CD133 and CD44 cell surface markers do not identify cancer stem cells in primary human gastric tumors. *J Cell Physiol* 2012; **227**: 2686-2693 [PMID: 21898409 DOI: 10.1002/jcp.23013]

63 **Zhao P**, Li Y, Lu Y. Aberrant expression of CD133 protein correlates with Ki-67 expression and is a prognostic marker in gastric adenocarcinoma. *BMC Cancer* 2010; **10**: 218 [PMID: 20487522 DOI: 10.1186/1471-2407-10-218]

64 **Mills JC**, Shivdasani RA. Gastric epithelial stem cells. *Gastroenterology* 2011; **140**: 412-424 [PMID: 21144849 DOI: 10.1053/j.gastro.2010.12.001]

65 **Haraguchi N**, Utsunomiya T, Inoue H, Tanaka F, Mimori K, Barnard GF, Mori M. Characterization of a side population of cancer cells from human gastrointestinal system. *Stem Cells* 2006; **24**: 506-513 [PMID: 16239320 DOI: 10.1634/stemcells.2005-0282]

66 **Ehata S**, Johansson E, Katayama R, Koike S, Watanabe A, Hoshino Y, Katsuno Y, Komuro A, Koinuma D, Kano MR, Yashiro M, Hirakawa K, Aburatani H, Fujita N, Miyazono K. Transforming growth factor-β decreases the cancer-initiating cell population within diffuse-type gastric carcinoma cells. *Oncogene* 2011; **30**: 1693-1705 [PMID: 21132002 DOI: 10.1038/con.2010.546]

67 **Zhang H**, Xi H, Cai A, Xia Q, Wang XX, Lu C, Zhang Y, Song Z, Wang H, Li Q, Chen L, Guo Z. Not all side population cells contain cancer stem-like cells in human gastric cancer cell lines. *Dig Dis Sci* 2013; **58**: 132-139 [PMID: 22878917 DOI: 10.1007/s10620-012-2330-1]

68 **Tang DG**. Understanding cancer stem cell heterogeneity and plasticity. *Cell Res* 2012; **22**: 457-472 [PMID: 22357481 DOI: 10.1038/cr.2012.13]

69 **Takebe N**, Miele L, Harris PJ, Jeong W, Bando H, Kahn M, Yang SX, Ivy SP. Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update. *Nat Rev Clin Oncol* 2015; **12**: 445-464 [PMID: 25850553 DOI: 10.1038/nrclinonc.2015.61]

70 **Li Y**, Laterra J. Cancer stem cells: distinct entities or dynamically regulated phenotypes? *Cancer Res* 2012; **72**: 576-580 [PMID: 22298594 DOI: 10.1158/0008-5472.CAN-11-3070]

71 **Fessler E**, Dijkgraaf FE, De Sousa E Melo F, Medema JP. Cancer stem cell dynamics in tumor progression and metastasis: is the microenvironment to blame? *Cancer Lett* 2013; **341**: 97-104 [PMID: 23089245 DOI: 10.1016/j.canlet.2012.10.015]

72 **Shin K**, Lim A, Odegaard JI, Honeycutt JD, Kawano S, Hsieh MH, Beachy PA. Cellular origin of bladder neoplasia and tissue dynamics of its progression to invasive carcinoma. *Nat Cell Biol* 2014; **16**: 469-478 [PMID: 24747439 DOI: 10.1038/ncb2956]

73 **Aggarwal BB**, Kunnumakkara AB, Harikumar KB, Gupta SR, Tharakan ST, Koca C, Dey S, Sung B. Signal transducer and activator of transcription-3, inflammation, and cancer: how intimate is the relationship?. *Ann N Y Acad Sci* 2009; **1171**: 59-76 [PMID: 19723038 DOI: 10.1111/j.1749-6632.2009.04911.x]

74 **Jiang YX**, Yang SW, Li PA, Luo X, Li ZY, Hao YX, Yu PW. The promotion of the transformation of quiescent gastric cancer stem cells by IL-17 and the underlying mechanisms. *Oncogene* 2017; **36**: 1256-1264 [PMID: 27524415 DOI: 10.1038/onc.2016.291]

75 **Kamran MZ**, Patil P, Gude RP. Role of STAT3 in cancer metastasis and translational advances. *Biomed Res Int* 2013; **2013**: 421821 [PMID: 24199193 DOI: 10.1155/2013/421821]

76 **Gong S**, Li Q, Jeter CR, Fan Q, Tang DG, Liu B. Regulation of NANOG in cancer cells. *Mol Carcinog* 2015; **54**: 679-687 [PMID: 26013997 DOI: 10.1002/mc.22340]

77 **Mohammed MK**, Shao C, Wang J, Wei Q, Wang X, Collier Z, Tang S, Liu H, Zhang F, Huang J, Guo D, Lu M, Liu F, Liu J, Ma C, Shi LL, Athiviraham A, He TC, Lee MJ. Wnt/β-catenin signaling plays an ever-expanding role in stem cell self-renewal, tumorigenesis and cancer chemoresistance. *Genes Dis* 2016; **3**: 11-40 [PMID: 27077077 DOI: 10.1016/j.gendis.2015.12.004]

78 **Vaiopoulos AG**, Kostakis ID, Athanasoula KCh, Papavassiliou AG. Targeting transcription factor corepressors in tumor cells. *Cell Mol Life Sci* 2012; **69**: 1745-1753 [PMID: 22527719 DOI: 10.1007/s00018-012-0986-5]

79 **Yoon C**, Cho SJ, Aksoy BA, Park DJ, Schultz N, Ryeom SW, Yoon SS. Chemotherapy Resistance in Diffuse-Type Gastric Adenocarcinoma Is Mediated by RhoA Activation in Cancer Stem-Like Cells. *Clin Cancer Res* 2016; **22**: 971-983 [PMID: 26482039 DOI: 10.1158/1078-0432.CCR-15-1356]

80 **Zhao Y**, Zhao L, Ischenko I, Bao Q, Schwarz B, Nieß H, Wang Y, Renner A, Mysliwietz J, Jauch KW, Nelson PJ, Ellwart JW, Bruns CJ, Camaj P. Antisense inhibition of microRNA-21 and microRNA-221 in tumor-initiating stem-like cells modulates tumorigenesis, metastasis, and chemotherapy resistance in pancreatic cancer. *Target Oncol* 2015; **10**: 535-548 [PMID: 25639539 DOI: 10.1007/s11523-015-0360-2]

81 **Chang L**, Graham P, Hao J, Ni J, Deng J, Bucci J, Malouf D, Gillatt D, Li Y. Cancer stem cells and signaling pathways in radioresistance. *Oncotarget* 2016; **7**: 11002-11017 [PMID: 26716904 DOI: 10.18632/oncotarget.6760]

82 **Cui J**, Li P, Liu X, Hu H, Wei W. Abnormal expression of the Notch and Wnt/β-catenin signaling pathways in stem-like ALDHhiCD44+ cells correlates highly with Ki-67 expression in breast cancer. *Oncol Lett* 2015; **9**: 1600-1606 [PMID: 25789008 DOI: 10.3892/ol.2015.2942]

83 **Balducci L**. In memory of Claude Jasmin: A prophet of Geriatric Oncology. *J Geriatr Oncol* 2018; **9**: 1-2 [PMID: 28978411 DOI: 10.1016/j.jgo.2017.09.004]

84 **Yoon C**, Park DJ, Schmidt B, Thomas NJ, Lee HJ, Kim TS, Janjigian YY, Cohen DJ, Yoon SS. CD44 expression denotes a subpopulation of gastric cancer cells in which Hedgehog signaling promotes chemotherapy resistance. *Clin Cancer Res* 2014; **20**: 3974-3988 [PMID: 24947926 DOI: 10.1158/1078-0432.CCR-14-0011]

85 **Bang YJ**, Im SA, Lee KW, Cho JY, Song EK, Lee KH, Kim YH, Park JO, Chun HG, Zang DY, Fielding A, Rowbottom J, Hodgson D, O'Connor MJ, Yin X, Kim WH. Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer. *J Clin Oncol* 2015; **33**: 3858-3865 [PMID: 26282658 DOI: 10.1200/JCO.2014.60.0320]

86 **Satoh T**, Xu RH, Chung HC, Sun GP, Doi T, Xu JM, Tsuji A, Omuro Y, Li J, Wang JW, Miwa H, Qin SK, Chung IJ, Yeh KH, Feng JF, Mukaiyama A, Kobayashi M, Ohtsu A, Bang YJ. Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study. *J Clin Oncol* 2014; **32**: 2039-2049 [PMID: 24868024 DOI: 10.1200/JCO.2013.53.6136]

87 **Trumpp A**, Essers M, Wilson A. Awakening dormant haematopoietic stem cells. *Nat Rev Immunol* 2010; **10**: 201-209 [PMID: 20182459 DOI: 10.1038/nri2726]

88 **Bautch VL**. Cancer: Tumour stem cells switch sides. *Nature* 2010; **468**: 770-771 [PMID: 21150987 DOI: 10.1038/468770a]

89 **Ricci-Vitiani L**, Pallini R, Biffoni M, Todaro M, Invernici G, Cenci T, Maira G, Parati EA, Stassi G, Larocca LM, De Maria R. Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. *Nature* 2010; **468**: 824-828 [PMID: 21102434 DOI: 10.1038/nature09557]

**Footnotes**

**Conflict-of-interest statement:** The author has no conflict of interest to declare.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** April 18, 2021

**First decision:** May 12, 2021

**Article in press:**

**Specialty type:** Oncology

**Country/Territory of origin:** Taiwan

**Peer-review report’s scientific quality classification**

Grade A (Excellent): A

Grade B (Very good): 0


Grade C (Good): 0

Grade D (Fair): 0


Grade E (Poor): 0

**P-Reviewer:** Rojas A **S-Editor:** Gong ZM **L-Editor:** A **P-Editor:** Gong ZM


**Figure Legends**



**Figure 1 Molecular properties of gastric cancer stem cells.** Main gastric cancer stem cells (GCSCs)-surface markers (such as CD44, CD44v, CD71, CD90, CD133, Lgr5, ALDH1, CXCR4, ABC, and Lrig1) and GCSC-intracellular markers (such as DOCK6, Mist1, MSI-1, NANOG, Oct3/4, and SOX2). GCSCs represent a subpopulation of cancer cells (non-CSCs) existing within heterogeneous tumors implicated in tumor initiation, growth, metastasis, and chemo-/radioresistance, antiapoptosis, cancer recurrence, and metastasis. However, a small number of non-CSCs can dedifferentiate and transform into GCSCs through TME-induced EMT. The newly generated GCSCs from non-CSCs, together with the intrinsic GCSCs, consequently contribute to recurrence and metastasis of cancer. CD44: cluster of differentiation 44; CD44v: CD44v: CD44 splice variant; CD71: cluster of differentiation 71; CD90: cluster of differentiation 90; CD133: cluster of differentiation 133; Lgr5: leucine-rich repeat-containing G-protein coupled receptor 5; ALDH1: aldehyde dehydrogenase 1; CXCR4: C-X-C chemokine receptor type 4; ABC: ATP-binding cassette subfamily; Lrig1: leucine rich repeats and immunoglobulin like domains protein 1; DOCK6: dedicator of cytokinesis 6; Mist1: muscle, intestine and stomach expression 1; MSI-1: musashi RNA binding protein 1; NANOG: nanog homeobox; Oct3/4: octamer-binding transcription factor 3/4; SOX2: sex determining region Y-box 2.



**Figure 2 The roles of gastric cancer stem cells in the tumor microenvironment and activated in gastric cancer stem cells.** This figure shows the dynamic regulation of the tumor niche and GCSCs. Cancer cells (non-CSCs) can dedifferentiate by regulating their intracellular signaling pathways, gene expression, and epigenetic modification through the functional connection of the tumor niche to differentiated cancer cells (non-CSCs) to obtain the GCSC phenotype. Stromal cells can support GCSCs development through various kinds of interactions. Tumor-associated macrophages (TAMs), cancer-associated fibroblasts (CAFs), tumor vascular endothelial cells (ECs) and hypoxia not only directly enhance the CSC capabilities of GCSCs by activating the several pathways but also inhibit T cells and dendritic cells (DCs) activity. TGF-β: transforming growth factor-β; SDF-1α: stromal cell-derived factor-1α;PD-1: programmed cell death 1; PD-L1: programmed cell death 1 Ligand 1; CD133: cluster of differentiation 133; MFG-E8: milk fat globule epidermal growth factor 8; NO: nitric oxide; eNOS: endothelial NO·synthase; IL-6: interleukin 6; MCP1: monocyte chemoattractant protein 1; VEGF: vascular endothelial growth factor.

****

**Figure 3 Four signal pathways contribute to stemness properties of cancer stem cells: Hedgehog, Notch/STAT3, NANOG, and Wnt/β-catenin pathways.** Hedgehog pathway: PTCH1-induced inhibition of SMO is reversed by HH binding with PTCH1, leading to the release of the complex of GLI from microtubules, with GLI protein entering the nucleus to transcriptionally activate downstream target genes.Notch/STAT3 pathway: DLL binding-induced Notch activation causes several kinase proteins activation, further converting STAT3 to a transcriptional activator to initiate downstream gene expression.NANOG pathway: Ligand binding-induced NANOG activation causes several kinase proteins activation, further converting STAT3 to a transcriptional activator to initiate downstream gene expression.Wnt/β-catenin pathway: Wnt binds to its receptor, Frizzled to activate LRP protein. The activated LRP protein enhances the phosphorylation of the kinase (a component of the cytoplasmic complex that promotes phosphorylation of β-catenin and its degradation), which inhibits the kinase, further causing the accumulation of free and unphosphorylated β-catenin in the cytoplasm that is then translocated to the nucleus. In the nucleus, β-catenin binds to other transcriptional factors to promote downstream target gene expression.

**Table 1 Potential gastric cancer stem cells cell-surface markers by using flow cytometric analysis**

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Cell-surface markers** | **Function** | **Physiological significance** | | | | | **Involved signaling pathways** | **Therapeutic targets or inhibitor** | **Prognostic marker of GC** | **Ref.** |
| **Tumorigenicity/GCSC generation** | **Spheroid formation** | **Chemo-resistance** | **Radio-resistance** | **EMT/metastasis** |
| CD44 | Hyaluronic acid receptor | ● | ● | ● | ND | ● | Wnt/β-catenin pathway | CD44 | ● | [[21-24](#_ENREF_21)] |
| CD44H | Hyaluronic acid receptor | ● | ● | ● | ND | ND | Wnt/β-catenin pathway | CD44 | ● | [[25](#_ENREF_25)] |
| CD44v | Hyaluronic acid receptor | ● | ● | ND | ND | ● | Glutathione metabolism | Glutathione metabolism  sulfasalazine (SSZ) | ● | [[25-28](#_ENREF_25)] |
| CD44+  CD24 | Cell adhesion molecule | ● | ● | ● | ND | ND | Notch pathway | CD44+CD24 | ● | [[24](#_ENREF_24),[29](#_ENREF_29)] |
| CD44+  CD54 | Cell adhesion molecule | ● | ● | ● | ND | ND | Wnt/β-catenin pathway | CD44+CD54 | ND | [[22](#_ENREF_22),[24](#_ENREF_24),[30](#_ENREF_30)] |
| CD44+  EpCAM | Cell adhesion molecule/epithelial cell adhesion molecule | ● | ● | ● | ND | ND | Wnt/β-catenin pathway | ND | ND | [[24](#_ENREF_24),[31](#_ENREF_31)] |
| CD71- | Transferrin receptor | ● | ND | ND | ND | ● | uptake of transferrin/iron | CD71 | ● | [[32](#_ENREF_32)] |
| CD90 | Immunoglobulin superfamily/  Thy-1 cell-surface antigen | ● | ● | ND | ND | ● | Notch pathway | CD90  trastuzumab | ND | [[24](#_ENREF_24),[33](#_ENREF_33)] |
| CD133 | Pentaspan transmembrane glycoprotein | ● | ● | ND | ND | ND | MAPK/ERK pathway | CD133 | ● | [[24](#_ENREF_24)] |
| Lgr5 | Leucine-rich repeat-containing G-protein coupled receptor 5 | ● | ND | ● | ND | ● | Notch-mTOR pathway | Notch-mTOR pathway  MiR-132  Anti-Lgr5 | ● | [[34-38](#_ENREF_34)] |
| ALDH1 | Aldehyde dehydrogenase 1 | ● | ● | ● | ● | ● | Wnt/β-catenin pathway | TGF-β | ● | [[39](#_ENREF_39)] |
| CD44+  CD166+  ALDH | Activated leukocyte cell adhesion molecule (ALCAM) | ● | ● | ● | ND | ● | Wnt/β-catenin pathway | CD44  CD166  TGF-β | ● | [[24](#_ENREF_24),[40](#_ENREF_40),[41](#_ENREF_41)] |
| CXCR4 | C-X-C chemokine receptor type 4 | ● | ● | ● | ND | ● | CXCR4/SDF-1  pathway | CXCR4 | ● | [[42](#_ENREF_42)] |
| ABCB1/MDR1  ABCG2 | ABC transporters | ● | ● | ● | ND | ● | JAK/STAT pathway  HH/PTCH1 pathway | ABCB1/MDR1  ABCG2 | ● | [[23](#_ENREF_23),[33](#_ENREF_33),[43-45](#_ENREF_43)] |
| SP | Side population | ● | ● | ● | ND | ● | Wnt/β-catenin pathway | ND | ● | [[21](#_ENREF_21),[23](#_ENREF_23),[44](#_ENREF_44),[46-48](#_ENREF_46)] |
| Lrig1 | Regulatory factor of cell cycle | ● | ● | ● | ND | ● | [ErbB](https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/erbb) pathway | Lrig1 | ● | [[49](#_ENREF_49)] |
| α2-, α5-, β3- and β5- integrins | Cell adhesion molecule | ● | ● | ND | ND | ● | p38/ERK pathway | Integrins | ND | [[23](#_ENREF_23)] |

●**:** determined; ND: not determined. CD44: cluster of differentiation 44; CD44v: CD44 splice variant; Lgr5: leucine-rich repeat-containing G-protein coupled receptor 5; ALDH1: aldehyde dehydrogenase 1; CXCR4: C-X-C chemokine receptor type 4; GCSCs: gastric cancer stem cells; GC: gastric cancer; EpCAM: epithelial cell adhesion molecule; Lgr5: leucine-rich repeat-containing G-protein coupled receptor 5; ABCB1: ATP-binding cassette subfamily B member 1; ABCG2: ATP-binding cassette subfamily G member 2; MDR1: multidrug resistance protein 1; SP: side population; Lrig1: leucine rich repeats and immunoglobulin like domains protein 1; SDF-1: stromal cell-derived factor-1; SSZ: sulfasalazine; TGF-β: transforming growth factor-β; HH: Hedgehog; PTCH1: patched homolog 1; MAPK: Mitogen-activated protein kinase; ERK: extracellular-signal-regulated kinase; JAK :Janus kinase; STAT3: signal transducer and activator of transcription 3; mTOR: mechanistic target of rapamycin; EMT: epithelial–mesenchymal transition; EGFR: epidermal growth factor receptor; miRNA: microRNA.

**Table 2 Potential gastric cancer stem cells intracellular markers**

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Intracellular markers** | **Function** | **Physiological significance** | | | | | **Involved signaling pathways** | **Therapeutic targets** | **Prognostic marker of GC** | **Ref.** |
| **Tumorigenicity/GCSC generation** | **Spheroid formation** | **Chemo-resistance** | **Radio-resistance** | **EMT/metastasis** |
| DOCK6 | Dock-C subfamily guanine nucleotide exchanger | ● | ● | ● | ● | ● | Wnt/β-catenin pathway | DOCK6 | ● | [[50](#_ENREF_50)] |
| Mist1 | Transcriptional factor | ● | ● | ● | ND | ● | Wnt/β-catenin pathway | Mist1 | ● | [[51](#_ENREF_51)] |
| MSI-1 | [RNA-binding protein](https://en.wikipedia.org/wiki/RNA_binding_protein) | ● | ● | ● | ND | ● | EGFR pathway | MSI-1 | ● | [[48](#_ENREF_48)] |
| NANOG | Transcription factor | ● | ● | ● | ND | ● | Wnt/β-catenin pathway  JAK-STAT pathway | NANOG | ● | [[23](#_ENREF_23),[52](#_ENREF_52)] |
| Oct3/4 | Octamer-binding transcription factor 3/4 | ● | ● | ● | ND | ● | Wnt/β-catenin pathway  JAK-STAT pathway | Oct3/4 | ● | [[23](#_ENREF_23),[53](#_ENREF_53)] |
| SOX2 | Sex determining region Y-box 2 | ● | ● | ● | ND | ● | Wnt/β-catenin pathway  JAK-STAT pathway | SOX2  MiR-134  all-trans retinoic acid | ● | [[52-57](#_ENREF_52)] |

●**:** determined; ND: not determined; DOCK6: dedicator of cytokinesis 6; Mist1: muscle, intestine and stomach expression 1; MSI-1: musashi RNA binding protein 1; GCSCs: gastric cancer stem cells; GC: gastric cancer; EMT: epithelial–mesenchymal transition; NANOG: nanog homeobox; Oct3/4: octamer-binding transcription factor 3/4; SOX2: sex determining region Y-box 2; MAPK: Mitogen-activated protein kinase; ERK: extracellular-signal-regulated kinase; JAK: Janus kinase; STAT3: signal transducer and activator of transcription 3; EGFR: epidermal growth factor receptor; miRNA: microRNA.

**Table 3 Regulators of gastric cancer stem cells-related pathway stimuli in gastric cancer stem cells stemless properties and gastric cancer stem cells-targeted therapy**

|  |  |  |  |
| --- | --- | --- | --- |
| **GCSCs pathway** | **Involved pathway proteins** | **Therapeutic inhibitor or drug** | **Ref.** |
| Hedgehog (HH) | PTCH1, SMO, GLI | Vismodegib  5E1  Robotnikinin  GANT58  GANT61  HPI1-4  Genistein  Resveratrol  Cyclopamine  Mir-218  Saridegib  BMS-833923  Erismodegib  PF-0449913  LY2940680 | [[27](#_ENREF_27),[28](#_ENREF_28),[83](#_ENREF_83),[84](#_ENREF_84)] |
| Notch/STAT3 | Notch ligands (DLL), Notch receptors, JAK, ERK, STAT3 | Napabucasin  Demclzumab (anti-DLL4)  Tarextumab  BBI-608 | [[28](#_ENREF_28),[76](#_ENREF_76),[85](#_ENREF_85),[86](#_ENREF_86)] |
| NANOG | NANOG, STAT3, Kinases | Napabucasin  BBI-608  BB1-503 | [[28](#_ENREF_28),[73](#_ENREF_73),[75](#_ENREF_75),[85](#_ENREF_85)] |
| Wnt/β-catenin | Wnt, β-catenin, LRP/FZD | Napabucasin  BBI-608  Vantictumab (anti-FZD)  LGK974  Foxy-5 | [[28](#_ENREF_28),[77](#_ENREF_77),[78](#_ENREF_78),[85](#_ENREF_85),[86](#_ENREF_86)] |

GCSCs: gastric cancer stem cells; HH: Hedgehog; NANOG: nanog homeobox; STAT3: signal transducer and activator of transcription 3; GLI: Glioma-associated oncogene; SMO: smoothened; PTCH1: patched homolog 1; ERK: extracellular-signal-regulated kinase; JAK: Janus kinase; Wnt: Wingless/int1; LRP: Lipoprotein receptor-related proteins/low density lipoprotein receptor-related proteins; FZD: Frizzled receptors; DLL: Notch ligands.